Studies have shown that there is no significant overlap between the patients with CEBPα mutation and patients with FLT3-ITD or MLL-PTD mutations, suggesting that CEBPα mutations define a distinct biologic subclass of NC-AML [42]. Here, CEBPA is linked to acute myeloid leukemia.